David Arkowitz

David Arkowitz, listed as finance chief, has filed trades across 5 companies (mainly through SEC (Form 4)), most often in Seres Therapeutics, Inc., Kineta, Inc./de and F-star Therapeutics, Inc. Over a trading history stretching from 10 May 2021 to 30 June 2025, the count stands at 11 filings.

In open-market terms, that means 1 purchase worth €49k on one side and 2 sales worth €18k on the other. Netting one side against the other leaves €30k of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 2 share grants and 4 option exercises. So far in 2025, the count stands at 1 purchase and no sales.

The latest filing, published on 2 July 2025, reports a transaction in Kineta, Inc./de. The latest purchase dates back some time: it was published 643 days ago, on 13 January 2025. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.